These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38349262)

  • 1. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
    Vagaggini C; Petroni D; D'Agostino I; Poggialini F; Cavallini C; Cianciusi A; Salis A; D'Antona L; Francesconi V; Manetti F; Damonte G; Musumeci F; Menichetti L; Dreassi E; Carbone A; Schenone S
    Drug Dev Res; 2024 Feb; 85(1):e22158. PubMed ID: 38349262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
    Nešović M; Divac Rankov A; Podolski-Renić A; Nikolić I; Tasić G; Mancini A; Schenone S; Pešić M; Dinić J
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[3,4-
    Kostić A; Jovanović Stojanov S; Podolski-Renić A; Nešović M; Dragoj M; Nikolić I; Tasić G; Schenone S; Pešić M; Dinić J
    Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34209342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-
    Jovanović Stojanov S; Kostić A; Ljujić M; Lupšić E; Schenone S; Pešić M; Dinić J
    Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells.
    Monteleone L; Marengo B; Musumeci F; Grossi G; Carbone A; Valenti GE; Domenicotti C; Schenone S
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
    Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
    J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
    Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
    Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Pyrazolo[3,4-
    Greco C; Taresco V; Pearce AK; Vasey CE; Smith S; Rahman R; Alexander C; Cavanagh RJ; Musumeci F; Schenone S
    ACS Med Chem Lett; 2020 May; 11(5):657-663. PubMed ID: 32435367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-
    Poggialini F; Vagaggini C; Brai A; Pasqualini C; Crespan E; Maga G; Perini C; Cabella N; Botta L; Musumeci F; Frosini M; Schenone S; Dreassi E
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-
    Fallacara AL; Zamperini C; Podolski-Renić A; Dinić J; Stanković T; Stepanović M; Mancini A; Rango E; Iovenitti G; Molinari A; Bugli F; Sanguinetti M; Torelli R; Martini M; Maccari L; Valoti M; Dreassi E; Botta M; Pešić M; Schenone S
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line.
    Cammarata FP; Torrisi F; Forte GI; Minafra L; Bravatà V; Pisciotta P; Savoca G; Calvaruso M; Petringa G; Cirrone GAP; Fallacara AL; Maccari L; Botta M; Schenone S; Parenti R; Cuttone G; Russo G
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
    Vignaroli G; Zamperini C; Dreassi E; Radi M; Angelucci A; Sanità P; Crespan E; Kissova M; Maga G; Schenone S; Musumeci F; Botta M
    ACS Med Chem Lett; 2013 Jul; 4(7):622-6. PubMed ID: 24900720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pyrazolo[3,4-
    Rango E; Pastorino F; Brignole C; Mancini A; Poggialini F; Di Maria S; Zamperini C; Iovenitti G; Fallacara AL; Sabetta S; Clementi L; Valoti M; Schenone S; Angelucci A; Ponzoni M; Dreassi E; Botta M
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.
    Calgani A; Vignaroli G; Zamperini C; Coniglio F; Festuccia C; Di Cesare E; Gravina GL; Mattei C; Vitale F; Schenone S; Botta M; Angelucci A
    Mol Cancer Ther; 2016 Jul; 15(7):1535-44. PubMed ID: 27196762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.
    Svec RL; Furiassi L; Skibinski CG; Fan TM; Riggins GJ; Hergenrother PJ
    ACS Chem Biol; 2018 Nov; 13(11):3206-3216. PubMed ID: 30296373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model.
    Schiapparelli P; Zhang P; Lara-Velazquez M; Guerrero-Cazares H; Lin R; Su H; Chakroun RW; Tusa M; Quiñones-Hinojosa A; Cui H
    J Control Release; 2020 Mar; 319():311-321. PubMed ID: 31911154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
    Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
    Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines.
    Torrisi F; Minafra L; Cammarata FP; Savoca G; Calvaruso M; Vicario N; Maccari L; Pérès EA; Özçelik H; Bernaudin M; Botta L; Russo G; Parenti R; Valable S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
    Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
    Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.